Login
$IRD
$4.10 +$0.06 (1.49%) After hours

$IRD SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G
12 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027

05 Nov 2026 Form 4: Magrath George, Director

Sold 28,258 shares ($110K)

03 Nov 2026 144
27 Oct 2026 SCHEDULE 13G
27 Oct 2026 Form 4: Schachle Joseph K, Chief Operating Officer

Sold 4,767 shares ($17K)

27 Oct 2026 Form 4: Yerxa Benjamin R, Director

Sold 33,189 shares ($117K)

27 Oct 2026 Form 4: Gagnon Robert E., Chief Financial Officer

Sold 14,000 shares ($49.6K)

27 Oct 2026 Form 4: Magrath George, Director

Sold 9,591 shares ($34.4K)

23 Oct 2026 144
23 Oct 2026 144
23 Oct 2026 144
21 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

15 Oct 2026 8-K: Regulation FD Disclosure

Prediction of Retinal Sensitivity Changes Following Treatment in BEST Disease George Magrath, MD Retina in Rio 2026

02 Oct 2026 Form 4: Foundation Fighting Blindness Retinal Degeneration Fund, Director and 1 other

Sold 556,000 shares ($2.76M)

11 Sep 2026 Form 4: Magrath George, Director

Received 392,157 shares by exercise or conversion ($451K) · Gave up 75,541 shares to cover exercise price or tax ($451K)

11 Sep 2026 8-K: Regulation FD Disclosure

OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support